Gamida Cell and Be The Match BioTherapies® Announce Strategic Collaboration
– Collaboration Aims to Expand the Use of Bone Marrow Transplant to Treat Hematologic Malignancies and Serious Blood Disorders –
Under the terms of the collaboration agreement,
The collaboration is expected to leverage a wide range of Be The Match BioTherapies’ research assets and services, including the Be The Match Registry®, the largest in the world with more than 20 million potential donors, as well as personalized case management and logistics services.
“Gamida Cell’s work to bring a new therapeutic option to patients in
need of a bone marrow transplant aligns with our core mission to help
organizations deliver cellular therapies that save more lives and
improve the quality of life for patients,” said
Despite the curative potential of bone marrow transplants, it is estimated that more than 40 percent of eligible patients in the U.S. do not receive one for various reasons, including difficulty in finding a matched donor.1 NiCord is designed to potentially serve as a universal alternative to existing donor sources for bone marrow transplant.
“Be the Match BioTherapies is a respected leader in cell therapy, with
especially deep roots in stem cell transplantation. Our two
organizations share the belief that new cell therapies are needed not
only to improve outcomes for patients undergoing stem cell transplants
but also to offer patients unable to find a matched donor the chance for
a successful transplant,” stated
About
About NiCord
NiCord, Gamida Cell’s lead clinical program, is
under development as a universal bone marrow transplant solution for
patients with high-risk hematologic malignancies. NiCord has been
granted breakthrough status by the
About Be The Match BioTherapies
Be
The Match BioTherapies is the only cell and gene therapy solutions
provider with customizable services to support the end-to-end cell
therapy supply chain. Backed by the industry-leading experience of the National
Marrow Donor Program/Be The Match, and a research partnership
with the CIBMTR® (
Be The Match BioTherapies is dedicated to providing high-quality
cellular starting material consented for research, clinical and
commercial use, developing and managing expansive cell collection
networks, and navigating cell therapy regulatory compliance. Using
proven infrastructure to successfully manage autologous and allogeneic
cell therapy supply chains, including MatchSource® Supply
Chain Software, personalized case managers and logistics experts,
the organization has a history of compliance managing the chain of
identity. The collaboration with CIBMTR extends services to include
long-term follow-up tracking for the first two
For more information, follow Be The Match BioTherapies on LinkedIn or Twitter at @BTMBioTherapies.
References
1
2ClinicalTrials.gov
identifier NCT02730299.
Gamida Cell Forward Looking Statements
This press release
contains forward-looking statements as that term is defined in the
Private Securities Litigation Reform Act of 1995, including with respect
to the strategic collaboration between
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005127/en/
Source:
Gamida Cell Contacts:
Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264
Krystle Gibbs (media)
krystle@tenbridgecommunications.com
508-479-6358
Be The Match BioTherapies:
Kate McDermott
kmcdermo@nmdp.org
612-280-2616